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Abstract
Objectives: To analyze the role of the capsular type in pneumococci causing relapse and reinfection episodes of acute
exacerbation in COPD patients.
Methods: A total of 79 patients with 116 recurrent episodes of acute exacerbations caused by S. pneumoniae were included
into this study (1995–2010). A relapse episode was considered when two consecutive episodes were caused by the same
strain (identical serotype and genotype); otherwise it was considered reinfection. Antimicrobial susceptibility testing
(microdilution), serotyping (PCR, Quellung) and molecular typing (PFGE/MLST) were performed.
Results: Among 116 recurrent episodes, 81 (69.8%) were reinfections, caused by the acquisition of a new pneumococcus,
and 35 (30.2%) were relapses, caused by a pre-existing strain. Four serotypes (9V, 19F, 15A and 11A) caused the majority
(60.0%) of relapses. When serotypes causing relapses and reinfection were compared, only two serotypes were associated
with relapses: 9V (OR 8.0; 95% CI, 1.34–85.59) and 19F (OR 16.1; 95% CI, 1.84–767.20). Pneumococci isolated from relapses
were more resistant to antimicrobials than those isolated from the reinfection episodes: penicillin (74.3% vs. 34.6%,
p,0.001), ciprofloxacin (25.7% vs. 9.9%, p,0.027), levofloxacin (22.9% vs. 7.4%, p = 0.029), and co-trimoxazole (54.3% vs.
25.9%, p,0.001).
Conclusions: Although the acquisition of a new S. pneumoniae strain was the most frequent cause of recurrences, a third of
the recurrent episodes were caused by a pre-existing strain. These relapse episodes were mainly caused by serotypes 9V
and 19F, suggesting an important role for capsular type.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a major
cause of morbidity and mortality in developed countries [1].
Approximately 50% of acute exacerbation episodes of COPD are
caused by bacterial pathogens, mainly Streptococcus pneumoniae,
Haemophilus influenzae and Moraxella catarrhalis [2]. The development
of an acute exacerbation episode caused by S. pneumoniae is thought
to be associated with the acquisition of a new strain, although
scarce information is available [3].
Capsular type, the principal pneumococcal virulence factor, had
been related to the ability of pneumococci to cause invasive disease
or colonization [4]. However, the aetiological role of pneumococ-
cal serotypes in relapse episodes of COPD patients remains to be
determined.
The aims of this study were to analyse the relationship between
serotype and genotype and the ability to cause relapse or
reinfection episodes in patients with COPD. In addition, we have
explored the influence of previous antimicrobial therapy in this
occurrence.
Results
Epidemiological and clinical data
A total of 79 COPD patients were included in the study. Their
mean age was 69 (SD 66) years, and 77 (97.5%) of them were
males. In terms of COPD severity there was 1 patient with mild
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(1.3%), 14 patients with moderate (17.7%), 18 patients with severe
(22.8%) and 39 patients with very severe (49.4%) airflow
obstruction. The GOLD status of the remaining 7 patients was
not available.
Fifty-two patients had $1 reinfections (caused by pneumococci
with different serotype and genotype), 16 had $1 relapses (caused
by the same pneumococcus), and the remaining 11 patients had
both relapses and reinfections. No differences were observed as
regards the age of patients with relapse or reinfection (69.969 vs.
70.569, respectively), nor in terms of COPD severity (GOLD II:
71.7613 vs. 69.268, respectively, GOLD III: 66.467 vs.
70.6611, respectively; and GOLD IV: 69.169 vs. 69.468,
respectively).
Finally, a total of 116 recurrent episodes from the 79 patients
were studied; of these, 35 (30.2%) were relapses and 81 (69.8%)
reinfections. The mean time between episodes was 166696 days,
being shorter among relapses (133689 days) than among
reinfections (181696 days; P = 0.020). Table 1 shows the
distribution of the episodes based on the mean time between
episodes. When the consecutive episodes occurred during a period
#120 days, significantly higher frequency of relapse episodes was
observed (57.1% vs. 35.8%, P = 0.033). Whereas, when the period
of time between episodes was higher than 240 days the frequency
of reinfection episodes was higher (14.3% vs. 30.9%, P = 0.061).
In 13 of the 35 (37.1%) relapses and in 31 of the 81 (38.3%)
reinfections, pneumococcal strains were isolated together with
other potential pathogens.
However, P. aeruginosa was more frequently isolated from
relapses than from reinfections (17.1% vs. 7.4%, respectively;
P= 0.108), whereas H. influenzae was more closely associated with
reinfections (2.9% vs. 23.5%; P= 0.006).
Serotyping and genotyping
Four of the 31 serotypes detected caused 60.0% of relapses.
These serotypes were 9V (17.1%), 19F (17.1%), 15A (14.3%) and
11A (11.4%). The most frequent serotypes isolated from reinfec-
tions were 15A (8.6%), 16F (7.4%), 3 (6.2%) and 33F (6.2%).
Statistically significant differences were only observed in two
serotypes associated with relapses when compared with reinfec-
tions: 9V (OR 8.0; 95% CI, 1.34–85.59) and 19F (OR 16.1; 95%
CI, 1.84–767.20) [Table 2].
Serotypes included in the polysaccharide pneumococcal 23-
valent (23vPPV) accounted for 74.3% (n = 26) of relapses, and
56.8% (n = 46) of reinfections. Whereas, the coverage of the 10-
valent (PCV-10) and 13-valent (PCV-13) pneumococcal conjugate
vaccines in all relapses were 40.0% (n = 16) and 54.3% (n = 19),
respectively; and the coverage of reinfections were 23.5% (n = 19)
and 34.6% (n = 28), respectively.
Seventeen PFGE patterns (related with 14 sequence types) were
observed among the relapses, with the most frequent clonal
complexes (CC) being CC1569V (22.9%), CC6315A,19F (17.1%),
CC8819F (11.4%), CC8119A,19F (8.6%) and CC2603 (5.7%).
Among reinfections, 56 different PFGE patterns were observed,
and the most frequent clones were CC6315A (7.4%), CC3016F
(7.4%), CC71733F (4.9%), CC1569V (4.9%), CC4223A,23F (3.7%),
CC6211A (3.7%), CC9710A (3.7%), CC1917F (3.7%) and CC2603
(3.7%).
Only the CC1569V genotype was associated with relapses (OR
5.8; 95% CI, 1.61–20.73). Serotype 19F was genetically hetero-
geneous [CC8819F (6.2%), CC8119F (2.9%), and CC6319F (2.9%)].
Antimicrobial consumption and susceptibility
Table 3 shows the activity of nine antimicrobials against
pneumococci isolated from relapses and reinfections. Resistance to
betalactams, fluoroquinolones and co-trimoxazole was higher
among the strains that caused relapses than among those causing
reinfections (P,0.01).
Table 1. Distribution of the number of relapses and reinfections based on the time between episodes.
Time between episodes (days) Relapses (n =35) Reinfections (n =81) P-value
#120 20 (57.1%) 29 (35.8%) 0.033
121–240 10 (28.6%) 27 (33.3%) 0.613
.240 5 (14.3%) 25 (30.9%) 0.061
doi:10.1371/journal.pone.0059027.t001
Table 2. Serotypes causing relapse and reinfection episodes
of acute exacerbations in COPD patients.
serotype relapses (n =35)
reinfections
(n =81) OR 95%CI
9V 6 (17,1%) 2 (2.5%) 8.00 1.34–85.59
19F 6 (17,1%) 1 (1.2%) 16.11 1.84–767.20
15A 5 (14,3)% 7 (8.6%) 1.75 0.41–7.01
11A 4 (11.4%) 3 (3.7%) 3.32 0.53–23.95
3 3 (8.6%) 5 (6.2%) 1.42 0.21–7.82
6C 2 (5.7%) 0 infinite 0.44–infinite
22F 2 (5.7%) 3 (3.7%) 1.57 0.13–14.36
19A 2 (5.7%) 4 (4.9%) 1.17 0.10–8.59
35B 1 (2.9%) 1 (1.2%) 2.33 0.03–186.68
33F 1 (2.9%) 5 (6.2%) 0.45 0.01–4.24
23F 1 (2.9%) 2 (2.5%) 1.16 0.02–22.99
23A 1 (2.9%) 2 (2.5%) 1.16 0.02–22.99
14 1 (2.9%) 4 (4.9%) 0.57 0.01–6.03
16F 0 6 (7.4%) 0 0.00–1.93
7F 0 4 (4.9%) 0 0.00–3.51
38 0 4 (4.9%) 0 0.00–3.51
31 0 4 (4.9%) 0 0.00–3.51
Non-typeable 0 4 (4.9%) 0 0.00–3.51
6B 0 3 (3.7%) 0 0.00–5.63
10A 0 3 (3.7%) 0 0.00–5.63
35F 0 2 (2.5%) 0 0.00–12.39
23B 0 2 (2.5%) 0 0.00–12.39
Other serotypes 0 10a
aSerotypes 1, 5, 9N/L, 12F, 15B/C, 17F, 18C, 24F, 29 and 34 were detected in only
one reinfection episode.
doi:10.1371/journal.pone.0059027.t002
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The most frequent antimicrobials consumed by these patients
during the episode prior to reinfection or relapse (n = 116) were
beta-lactams (49.2%), fluoroquinolones (25.9%) or both (5.2%).
Consumption of fluoroquinolones during the previous episode was
higher in relapses than in reinfections (40.0% vs. 19.8%,
respectively; P = 0.02), whereas, no differences in the betalactams
consumption was observed (25.7% of relapses and 27.1% of
reinfections; P = 0.872).
Discussion
Capsular type is known to play an important role in the
invasiveness of pneumococcal strains [4]. Thus, some serotypes
have been associated with invasive pneumococcal disease or with
acute exacerbations of COPD [5]. Although the isolation of a new
pneumococcal strain has been associated with a significantly
increased risk of a new acute exacerbation [2], little information is
available about the persistence of S. pneumoniae isolates.
Our results agree with other reports in which reinfection
through acquisition of a new strain was the most frequent cause of
acute exacerbation episodes [3]. However, our study shows that a
third of these recurrences were caused by a persistent pneumo-
coccal strain, suggesting that in COPD patients the persistence of
the same strain could be underestimated.
Although in 12 of 35 relapses S. pneumoniae was isolated together
with another pathogen (P. aeruginosa, H. influenzae, M. catarrhalis or
Staphylococcus aureus) the role of S. pneumoniae in causing the acute
exacerbation episodes is supported by the high predominance of
Gram positive diplococci in the Gram stain of a good quality
sputum sample.
Our results show that serotypes 9V and 19F were associated
with relapses, suggesting that serotype could play an important
role in the persistence of pneumococcal isolates. In addition,
differences in genotype distribution were also detected. All isolates
that expressed the serotype 9V belonged to the Spain9V-CC156;
hence, this clone was associated with the relapse episodes. In
contrast, several genotypes expressed the serotype 19F and none of
them was significantly associated with relapses. These results
suggest that capsular type, rather than genetic background, may
play an important role in the persistence of pneumococci among
COPD patients.
Most of the patients included in the study had severe or very
severe COPD, suffering frequent episodes of acute exacerbation
and they received multiple antibiotic courses [6]. Although there
were no differences in the betalactam consumption among groups,
the betalactam resistance rates were higher among relapse
episodes. This finding could be explained because relapse episodes
were caused by few multi-resistant clones (mainly CC156 and
CC88). Whereas, strains causing reinfection episodes showed a
higher genetic diversity including penicillin-susceptible and -
resistant clones. However, we found an association between
fluorquinolone consumption and development of resistance. In
fact, the development of fluorquinolone resistance during or after
an antimicrobial course has been largely described in the literature
[7–8].
The proportion of serotypes covered by the 23vPPV vaccine
was high, especially those causing relapses. Unfortunately,
vaccination data of patients included in the present study was
not available; however, its protective efficacy in COPD popula-
tions is controversial since COPD adults respond differently than
the general adult population, due to their impaired antibody
response to the vaccine, the colonization of the lower respiratory
tract, or the frequent use of inhaled corticosteroids [9]. In the
other hand, conjugate vaccines (PV10 and PCV13) vaccine, which
have an enhanced immunity potential, could prevent the 40% and
a half of the overall relapse episodes, respectively.
The major limitations of our study are the low number of
relapse episodes, and also that it is a retrospective study.
Nonetheless, our study provides new data about the association
of certain serotypes with the persistence of pneumococci and the
ability to some clones, especially Spain9V-CC156, to cause relapse
episodes. In addition, our study suggests that new episodes that
occurred within the first 3 months after a previous one, had higher
probability to be caused by the same pneumococcal strain and this
fact could help to give an adequate empirical therapy.
Table 3. In vitro activity of nine antimicrobials against pneumococci isolated from relapses and reinfections
Relapses (n =35) Reinfections (n=81) P-valuef
Antibiotic
MIC50
(mg/L)
MIC90
(mg/L)
MIC range
(mg/L) % S % I % R
MIC50
(mg/L)
MIC90
(mg/L)
MIC range
(mg/L) % S % I % R
Penicillin 0.5 4 #0.03–4 25.7a 45.7 28.6 0.06 0.5 #0.03–2 65.4a 28.4 6.2 0.000
82.9b 17.1 0 98.8b 1.2 0 0.003
Cefotaxime 0.12 1 #0.03–2 68.6c 28.6 2.9 0.05 0.5 #0.03–1 92.6c 7.4 0 0.001
97.1d 2.9 0 100d 0 0 0.302
Ciprofloxacine 1 .32 #0.5–.32 74.3 – 25.7 #0.5 1 #0.5–.32 90.1 – 9.9 0.027
Levofloxacin #0.5 .32 #0.5–.32 77.1 2.9 20.0 #0.5 1 #0.5–.32 92.6 0 7.4 0.029
Tetracycline #2 .32 #2–.32 54.3 2.9 42.8 #2 .32 #2–.32 70.4 0 29.6 0.205
Erythromycin #0.25 .32 #0.25–.32 57.1 0 42.9 #0.25 .32 #0.25–.32 67.9 0 32.1 0.266
Clindamycin #0.25 .32 #0.25–.32 57.1 0 42.9 #0.25 .32 #0.25–.32 65.4 0 34.6 0.396
Chloramphenicol #2 .8 #2–.8 88.6 – 11.4 #2 8 #2–.8 93.8 – 6.2 0.081
Co-trimoxazole 2/38 .4/76 #0.5/9.5–.4/76 45.7 5.7 48.6 #0.5/9.5 .4/76 #0.5/9.5–.4/76 74.1 1.2 24.7 0.000
Clinical Laboratory Standard Institute (CLSI) breakpoints: aPenicillin oral breakpoints: susceptible #0.06 mg/L, intermediate 0.12–1 mg/L and resistant $2 mg/L.
bPenicillin parenteral (non-meningitis) breakpoints: susceptible #2 mg/L, intermediate 4 mg/L and resistant $8 mg/L. cCefotaxime (meningitis) breakpoints:
susceptible #0.5 mg/L, intermediate 1 mg/L and resistant $2 mg/L. dCefotaxime parenteral (non-meningitis) breakpoints: susceptible #1 mg/L, intermediate 2 mg/L
and resistant $4 mg/L. eNon-susceptibility to ciprofloxacin breakpoint MIC $4 mg/L and susceptibility breakpoint #2 mg/L. fP-value comparing susceptible strains.
doi:10.1371/journal.pone.0059027.t003
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Further studies with a high number of recurrent episodes are
now needed to investigate not only the role of capsular type in
relapses of acute exacerbations, but also whether the pneumococ-
cal conjugate vaccine 13 could be beneficial for COPD patients.
Methods
Study design
Pneumococci and other potential pathogens isolated from
sputum samples were prospectively collected into our laboratory
between 1995 and 2010, and were frozen at 280uC for further
analysis. Only pneumococci isolated from good quality sputum
were considered (,10 squamous cells and.25 leucocytes per low-
power field), with a predominance of Gram positive diplococci.
All COPD patients (n = 79) with two or more acute exacerba-
tion episodes and seen at the Bellvitge University Hospital during
the study period were included, after retrospective review of their
computerized medical charts. Only those consecutive acute
exacerbations which lasted for between four weeks and one year
were included in the study.
The severity of airflow obstruction was categorized according to
the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) criteria [10].
An acute exacerbation of COPD was defined as any sustained
increase in respiratory symptomatology compared with the
baseline situation requiring an increase in regular medication
and hospital treatment. A ‘relapse’ episode was defined as two or
more consecutive acute exacerbations caused by the same
pneumococcus (identical serotype and genotype). When the
consecutive episodes were caused by pneumococci with different
serotype and Pulsed Field Gel Electrophoresis (PFGE) pattern they
were defined as ‘reinfection’.
Ethical statement
This study and publication of the results were approved by the
‘Comite´ E`tic d’Investigacio´ Clı´nica del Hospital Universitari de
Bellvitge’ and the written or oral informed consent was considered
not necessary, because the source of bacterial isolates was
anonymized and the study was retrospective.
Serotyping and genotyping
Serotyping was performed by multiplex PCR, using a previously
described methodology [11]. All isolates were genotyped by
PFGE. Multi Locus Sequence Typing (MLST) was performed on
all relapse isolates in order to confirm the identity of the isolates
[12–13].
Antimicrobial susceptibility
Antimicrobial susceptibility was tested by microdilution
(STRHAE, SensititreTM), following the Clinical Laboratory
Standards Institute (CLSI) criteria [14]. The ciprofloxacin MIC
of resistant strains (MIC $4 mg/L) was confirmed by E-test. S.
pneumoniae ATCC49619 was used as the control strain.
Statistical analysis
Statistical analyses were carried out using SPSS 18 for
Windows. The odds ratios (OR) and 95% confidence intervals
(CI) were calculated, and Fisher’s exact test was used when
appropriate. Two-sided P values ,0.05 were considered statisti-
cally significant.
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